How Pirfenidone API Powder Is Manufactured: From Synthesis to Packed Drum

By Jignesh Akbari, Director | Published by SNJ Labs Pvt. Ltd. on 24 September 2026

Pirfenidone looks like a simple molecule: a small pyridone ring with a methyl group and a phenyl group attached. Making it at commercial scale, to pharmacopoeial quality, batch after batch, is a different matter. Every step, from starting materials to the final sieved powder, influences purity, impurity profile and particle size.

This article gives an overview of how a Pirfenidone API powder manufacturer produces the drug, and the GMP controls that make the difference between a compliant batch and a consistent one. To discuss supply, visit our Pirfenidone API powder manufacturer page. For a general introduction, see how active pharmaceutical ingredients are manufactured.

The Chemistry in Brief

Pirfenidone is 5-methyl-1-phenyl-2(1H)-pyridinone (CAS 53179-13-8, C₁₂H₁₁NO). Published routes commonly build it by attaching a phenyl group to the nitrogen of 5-methyl-2(1H)-pyridinone. This N-arylation typically uses a halobenzene, a copper catalyst and a base at elevated temperature. Manufacturers develop and validate their own optimised versions of such routes to improve yield, purity and safety.

Two practical consequences follow from this chemistry:

Starting material quality matters: impurities in key starting materials can carry through into the final API.
Catalyst residues must be removed: where a metal catalyst is used, residual metal must be controlled under ICH Q3D.

Manufacturing Steps

Stage	What happens	Key control
1. Raw material release	Starting materials, solvents and reagents are sampled and tested	Supplier qualification and specifications
2. Reaction	The coupling reaction runs in glass-lined or stainless steel reactors	Temperature, time and reaction completion checked by HPLC
3. Work-up	Catalyst, salts and by-products are removed by washing, extraction and filtration	Removal of metal residues and inorganic salts
4. Crude isolation	Crude pirfenidone is crystallised and isolated by centrifuge or filter	Yield and crude purity
5. Purification	Recrystallisation, sometimes with carbon treatment, raises purity	Related substances and colour
6. Drying	Wet cake is dried in vacuum or fluid bed dryers	Loss on drying and residual solvents
7. Milling and sieving	Powder is milled or micronized and sieved	Particle size distribution
8. Blending and packing	Batches are blended if required and packed in lined drums	Uniformity, labelling and containment
9. QC release	Finished API is fully tested against specification	Certificate of analysis and QA release

Final steps such as drying, milling and packing take place in controlled areas to protect the API from contamination. See our manufacturing blocks and infrastructure.

Controlling Impurities

Organic impurities: unreacted starting materials, by-products and degradation products are controlled per ICH Q3A and the pharmacopoeial monograph.
Residual solvents: solvents used in reaction and crystallisation are controlled per ICH Q3C.
Elemental impurities: catalyst metals and other elements are assessed per ICH Q3D.
Mutagenic and nitrosamine risks: manufacturers assess the route for potential mutagenic impurities (ICH M7) and nitrosamine formation, as regulators increasingly expect.

Why Particle Size Is a Manufacturing Decision

Pirfenidone is a high-dose drug, so the API forms most of the tablet weight. The formulator's process depends on consistent particle size. Milling or micronization is therefore a controlled, validated step rather than a finishing touch. Crystallisation conditions upstream also shape particle size and crystal habit, so a good manufacturer controls both. Read more in Pirfenidone API powder properties and specifications.

GMP Systems Behind Every Batch

ICH Q7 and WHO-GMP: the framework for API manufacturing quality.
Process validation: demonstrates that the process consistently produces API meeting specification.
Cleaning validation: prevents cross-contamination in multi-product facilities.
Equipment qualification: reactors, dryers and mills are qualified and maintained. See our engineering and utility systems.
Change control: any change to route, equipment or supplier is assessed and, where required, notified to customers.
Deviation and CAPA management: investigates problems and prevents recurrence.
Laboratory controls: validated methods and data integrity in the QA and QC department.

The Role of R&D

Route development and optimisation happen in R&D before scale-up. R&D teams improve yield, reduce impurities, select safer and greener solvents, and develop analytical methods. They also support customers with technical and analytical queries. Explore our R&D department.

Safety and Environment

API manufacturing involves solvents, reactive chemicals and heat, so process safety and environmental control are part of responsible production. Learn about our environment and safety practices.

SNJ Labs: Pirfenidone API Powder Manufacturer in Rajkot

Established in 2013, SNJ Labs Pvt. Ltd. manufactures active pharmaceutical ingredients and drug intermediates at a WHO-GMP approved, fully auditable facility in Rajkot, Gujarat. We produce Pirfenidone API in IP, USP, BP and EP grades, with complete in-house analysis and documentation support. We also offer third-party API contract manufacturing. Read more about us as a pharma API manufacturer.

Frequently Asked Questions

How is pirfenidone synthesised?

Published routes commonly make pirfenidone by N-arylation of 5-methyl-2(1H)-pyridinone with a halobenzene in the presence of a copper catalyst and a base. Manufacturers use their own optimised and validated versions of such routes, followed by purification to pharmacopoeial quality.

What GMP standard applies to Pirfenidone API manufacturing?

API manufacturing follows ICH Q7, the international GMP guide for active pharmaceutical ingredients, along with national requirements such as WHO-GMP and the rules of the regulators in each target market.

Why are elemental impurities important for Pirfenidone API?

If a synthesis uses a metal catalyst, such as copper, residues must be controlled in the final API. ICH Q3D requires a risk assessment of elemental impurities, and manufacturers set controls to keep them within permitted limits.

Does Pirfenidone API need milling or micronization?

Many formulators specify a particle size distribution for Pirfenidone API. Manufacturers use milling or micronization and sieving to achieve the agreed PSD consistently, because particle size affects flow, blend uniformity and dissolution.

How does a manufacturer ensure batch-to-batch consistency?

Consistency comes from controlling starting materials, validating the process, running in-process checks at critical steps, following standard operating procedures, testing every batch in the QC laboratory and managing any change through formal change control.

Visit or Audit Our Facility

We welcome customer audits and technical discussions. Contact SNJ Labs or download our catalogue.